Logo image of MPLT

MAPLIGHT THERAPEUTICS INC (MPLT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MPLT - US56565P1030 - Common Stock

18.63 USD
+0.18 (+0.98%)
Last: 12/9/2025, 1:49:37 PM
Fundamental Rating

2

Taking everything into account, MPLT scores 2 out of 10 in our fundamental rating. MPLT was compared to 531 industry peers in the Biotechnology industry. While MPLT has a great health rating, there are worries on its profitability. MPLT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MPLT has reported negative net income.
In the past year MPLT has reported a negative cash flow from operations.
MPLT Yearly Net Income VS EBIT VS OCF VS FCFMPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

MPLT's Return On Assets of -154.27% is on the low side compared to the rest of the industry. MPLT is outperformed by 86.44% of its industry peers.
Looking at the Return On Equity, with a value of -203.52%, MPLT is doing worse than 69.49% of the companies in the same industry.
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MPLT Yearly ROA, ROE, ROICMPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100

1.3 Margins

MPLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MPLT Yearly Profit, Operating, Gross MarginsMPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for MPLT remains at a similar level compared to 1 year ago.
MPLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MPLT Yearly Shares OutstandingMPLT Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MPLT Yearly Total Debt VS Total AssetsMPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 15.00 indicates that MPLT is not in any danger for bankruptcy at the moment.
MPLT has a better Altman-Z score (15.00) than 86.06% of its industry peers.
There is no outstanding debt for MPLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15
ROIC/WACCN/A
WACCN/A
MPLT Yearly LT Debt VS Equity VS FCFMPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.89 indicates that MPLT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.89, MPLT is in line with its industry, outperforming 54.80% of the companies in the same industry.
A Quick Ratio of 4.89 indicates that MPLT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.89, MPLT is in line with its industry, outperforming 55.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.89
MPLT Yearly Current Assets VS Current LiabilitesMPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

MPLT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.26%.
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -29.35% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-185.06%
EPS Next 2Y-41.26%
EPS Next 3Y-29.35%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MPLT Yearly EPS VS EstimatesMPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MPLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MPLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLT Price Earnings VS Forward Price EarningsMPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MPLT Per share dataMPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as MPLT's earnings are expected to decrease with -29.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.26%
EPS Next 3Y-29.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MPLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAPLIGHT THERAPEUTICS INC

NASDAQ:MPLT (12/9/2025, 1:49:37 PM)

18.63

+0.18 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners8.45%
Inst Owner ChangeN/A
Ins Owners4.37%
Ins Owner Change91.97%
Market Cap813.01M
Revenue(TTM)N/A
Net Income(TTM)-129.76M
Analysts88.89
Price Target31.62 (69.73%)
Short Float %1.98%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.75
P/tB 12.75
EV/EBITDA N/A
EPS(TTM)-3.13
EYN/A
EPS(NY)-3.74
Fwd EYN/A
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0
BVpS1.46
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.89
Altman-Z 15
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)107.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
EPS Next Y-185.06%
EPS Next 2Y-41.26%
EPS Next 3Y-29.35%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.55%
OCF growth 3YN/A
OCF growth 5YN/A

MAPLIGHT THERAPEUTICS INC / MPLT FAQ

What is the fundamental rating for MPLT stock?

ChartMill assigns a fundamental rating of 2 / 10 to MPLT.


What is the valuation status for MPLT stock?

ChartMill assigns a valuation rating of 0 / 10 to MAPLIGHT THERAPEUTICS INC (MPLT). This can be considered as Overvalued.


How profitable is MAPLIGHT THERAPEUTICS INC (MPLT) stock?

MAPLIGHT THERAPEUTICS INC (MPLT) has a profitability rating of 0 / 10.


What is the expected EPS growth for MAPLIGHT THERAPEUTICS INC (MPLT) stock?

The Earnings per Share (EPS) of MAPLIGHT THERAPEUTICS INC (MPLT) is expected to decline by -185.06% in the next year.